Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
2018 marks 100 years since some women, and all men, could vote. Find out how you can join in
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Health and Social Care Committee
Report published on Wednesday 21 March 2018. Government Response published on Friday 6 July 2018.
The UK’ s withdrawal from the European Union (EU) and the European Atomic Energy Community (Euratom) means new regulatory arrangements must be put in place from 29 March 2019 to guarantee the safe and effective supply of medicines, medical devices, medical products and substances of human origin in the UK. Patients, the NHS and the UK's life science industry need certainty about what the UK's regulatory arrangements will be after Brexit and a smooth transition towards them. There are also major implications for the future of medical research and development. The Health Committee invites submissions on the options available to the UK Government, including the respective opportunities, risks and trade-offs involved.
The Health Committee would like to receive written submissions on the following questions:
The Health Committee is responsible for scrutinising the work of the Department of Health and its associated public bodies. Submissions should therefore address matters for which the Secretary of State for Health is responsible. However, comments are welcome on matters where the Secretary of State for Health may not have lead responsibility, but where the withdrawal negotiations have important implications for the safe and effective supply of medicines, medical devices, medical products and substances of human origin in the UK.
Respondents need not provide responses to all questions. Equally, if there are any crucial issues not captured under the questions we pose, please highlight what they are and explain their salience. Written submissions should not exceed 3000 words and should be submitted by Thursday 26 October 2017. Public hearings are expected to be held in November and December 2017.
Evidence given by Rt Hon Jeremy Hunt, Secretary of State for Health and Social Care, Lord O'Shaughnessy, Parliamentary Under Secretary of State at the Department of Health and Social Care, Dr Ian Hudson, Chief Executive, Medicines and Healthcare products Regulatory Agency
Evidence given by Professor Alan Boyd, President of Faculty of Pharmaceutical Medicine, Academy of Medical Royal Colleges, Emma Greenwood, Director of Policy, Cancer Research UK, John Maingay, Director of Policy and Public Affairs, British Heart Foundation, Sir Hugh Taylor, Co-Chair, Brexit Health AllianceHugo Fry, UK General Manager, Sanofi, Warwick Smith, Director General, British Generic Manufacturers Association, Phil Thomson, President, Global Affairs, GlaxoSmithKline, John Wilkinson, Partner, Cooley LLP
There are currently no public meetings scheduled.
Health Committee publishes correspondence with the Secretary of State